We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Cardinal Health (NYSE: CAH) today announced its efforts to commercialize and broaden access to over-the-counter rapid COVID-19 tests through partnerships with Abbott and Quidel Corporation ("Quidel").
Beckman Coulter, a global clinical diagnostics leader, announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers.
Quidel has received a CE mark for its Savanna molecular testing platform and its first assay panel – the Savanna RVP4 Assay – allowing the company to market and sell the system in Europe.